BR112015017815A2 - método para prever o início dos sintomas extrapiramidais (eps) induzidos por um tratamento a base de antipsicótico - Google Patents

método para prever o início dos sintomas extrapiramidais (eps) induzidos por um tratamento a base de antipsicótico

Info

Publication number
BR112015017815A2
BR112015017815A2 BR112015017815A BR112015017815A BR112015017815A2 BR 112015017815 A2 BR112015017815 A2 BR 112015017815A2 BR 112015017815 A BR112015017815 A BR 112015017815A BR 112015017815 A BR112015017815 A BR 112015017815A BR 112015017815 A2 BR112015017815 A2 BR 112015017815A2
Authority
BR
Brazil
Prior art keywords
eps
onset
predicting
induced
extrapyramidal symptoms
Prior art date
Application number
BR112015017815A
Other languages
English (en)
Other versions
BR112015017815B1 (pt
Inventor
Lafuente Flo Amalia
Malagelada Grau Cristina
Bernardo Arroyo Miquel
Gassó Astorga Patricia
Mas Herrero Sergi
Original Assignee
Centro De Investig Biomedica En Red Ciber
Hospital Clinic Barcelona
Inst Dinvestigacions Biomediques August Pi I Sunyer
Univ Barcelona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro De Investig Biomedica En Red Ciber, Hospital Clinic Barcelona, Inst Dinvestigacions Biomediques August Pi I Sunyer, Univ Barcelona filed Critical Centro De Investig Biomedica En Red Ciber
Publication of BR112015017815A2 publication Critical patent/BR112015017815A2/pt
Publication of BR112015017815B1 publication Critical patent/BR112015017815B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

1/1 resumo “método para prever o início dos sintomas extrapiramidais (eps) induzidos por um tratamento a base de antipsicótico” a invenção diz respeito a métodos para prever o início dos sintomas extrapiramidais (eps) induzidos por um tratamento à base de antipsicóticos bem como métodos para fornecer medicamento personalizado a pacientes com base na sequência de vários snps associados com o início de eps. a invenção diz respeito também a kits para realizar o diagnóstico e métodos de medicina preventiva.
BR112015017815-4A 2013-01-25 2014-01-24 Método para prever o início dos sintomas extrapiramidais (eps) induzidos por um tratamento a base de antipsicótico BR112015017815B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13382027 2013-01-25
EP13382027.4 2013-01-25
PCT/EP2014/051369 WO2014114734A1 (en) 2013-01-25 2014-01-24 Method for predicting the onset of extrapyramidal symptoms (eps) induced by an antipsychotic-based treatment

Publications (2)

Publication Number Publication Date
BR112015017815A2 true BR112015017815A2 (pt) 2017-11-21
BR112015017815B1 BR112015017815B1 (pt) 2022-06-14

Family

ID=47681823

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015017815-4A BR112015017815B1 (pt) 2013-01-25 2014-01-24 Método para prever o início dos sintomas extrapiramidais (eps) induzidos por um tratamento a base de antipsicótico

Country Status (12)

Country Link
US (2) US9822415B2 (pt)
EP (1) EP2948563B1 (pt)
JP (2) JP6695142B2 (pt)
KR (1) KR102033813B1 (pt)
CN (1) CN104937113B (pt)
AR (1) AR095658A1 (pt)
BR (1) BR112015017815B1 (pt)
CA (1) CA2898414C (pt)
ES (1) ES2764154T3 (pt)
IL (1) IL240129B (pt)
MX (1) MX371426B (pt)
WO (1) WO2014114734A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2764154T3 (es) 2013-01-25 2020-06-02 Univ Barcelona Método para la predicción de la aparición de sintomas extrapiramidales (sep) inducidos por un tratamiento basado en antipsicóticos
US11091792B2 (en) * 2016-05-04 2021-08-17 Children's Hospital & Research Center At Oakland Rapid extraction of nucleic acids from clinical samples for downstream applications
WO2018202740A1 (en) * 2017-05-04 2018-11-08 Universitat De Barcelona Method for predicting early onset and severity of levodopa induced dyskinesia (lid) in subjects diagnosed of parkinson disease (pd)
JP6935079B2 (ja) * 2017-05-09 2021-09-15 国立大学法人千葉大学 機能的ｓｎｐの組合せ解析

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090104598A1 (en) * 2006-04-20 2009-04-23 Centre For Addiction And Mental Health Dopamine D2 receptor gene variants
ATE523602T1 (de) * 2006-06-12 2011-09-15 Hadasit Med Res Service Mit durch antipsychotika induzierten extrapyramidalen symptomen assoziierte rgs2- genotypen
US20090042194A1 (en) * 2006-12-18 2009-02-12 Maria Arranz Predicting a response to risperidone
EP2231871B1 (en) * 2008-01-02 2012-06-27 Suregene LLC Genetic markers of mental illness
CA2712075A1 (en) * 2008-01-17 2009-07-23 Suregene Llc Genetic markers of mental illness
JP5465241B2 (ja) 2008-05-29 2014-04-09 アルバニー モレキュラー リサーチ， インコーポレイテッド ５−ｈｔ３受容体調節物質ならびにその作製方法および使用
EP2342361A4 (en) * 2008-09-25 2012-11-14 Suregene Llc GENETIC MARKERS FOR A RISK ASSESSMENT OF THE DEVELOPMENT OF A MANIC-DEPRESSIVE DISEASE
US7972793B2 (en) * 2009-11-04 2011-07-05 Suregene, Llc Methods and compositions for the treatment of psychotic disorders through the identification of the SULT4A1-1 haplotype
US20110223597A1 (en) * 2010-03-10 2011-09-15 The Penn State Research Foundation Methods relating to olanzapine pharmacogenetics
US20130078637A1 (en) * 2010-05-27 2013-03-28 Hadasit Medical Research Services And Development Ltd. Antipsychotic-induced parkinsonism genotypes and methods of using same
TWI535535B (zh) 2012-07-06 2016-06-01 聖高拜磨料有限公司 用於低速研磨操作之磨料物品
ES2764154T3 (es) 2013-01-25 2020-06-02 Univ Barcelona Método para la predicción de la aparición de sintomas extrapiramidales (sep) inducidos por un tratamiento basado en antipsicóticos

Also Published As

Publication number Publication date
WO2014114734A1 (en) 2014-07-31
CA2898414A1 (en) 2014-07-31
JP6695142B2 (ja) 2020-05-20
MX371426B (es) 2020-01-24
US9822415B2 (en) 2017-11-21
BR112015017815B1 (pt) 2022-06-14
KR102033813B1 (ko) 2019-10-17
EP2948563A1 (en) 2015-12-02
KR20150107885A (ko) 2015-09-23
MX2015009726A (es) 2015-11-06
JP2020089370A (ja) 2020-06-11
CN104937113B (zh) 2021-07-30
CN104937113A (zh) 2015-09-23
IL240129A0 (en) 2015-09-24
EP2948563B1 (en) 2019-10-02
US20180230541A1 (en) 2018-08-16
ES2764154T3 (es) 2020-06-02
AR095658A1 (es) 2015-11-04
CA2898414C (en) 2021-11-02
US20150354005A1 (en) 2015-12-10
US10954563B2 (en) 2021-03-23
JP2016512950A (ja) 2016-05-12
IL240129B (en) 2020-01-30

Similar Documents

Publication Publication Date Title
CY1120390T1 (el) Συνθεση και μεθοδος για διαγνωση και θεραπεια ασθενειων που σχετιζονται με εκφυλισμο νευριτων
CY1121203T1 (el) Θεραπευτικες χρησεις της εμπαγλιφλοζινης
BR112015022472A2 (pt) método e sistema para prever a resposta a tratamentos para transtornos mentais
CL2015002127A1 (es) Sistemas y métodos para soporte de decisión clínica.
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
CR20140020A (es) Compuestos inhibidores de metaloenzimas
UY33863A (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
BR112016004305A2 (pt) métodos diagnósticos e composições para tratamento de glioblastoma
MX2013000675A (es) Metodo para identificar a un paciente con incrementada probabilidad de responder a una terapia anticancer.
CL2015002434A1 (es) Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina.
WO2014200952A3 (en) Genetic markers of antipsychotic response
FR2975600B1 (fr) Agents pour le traitement de tumeurs
BR112015017241A2 (pt) doadores de nitroxil com índice terapêutico melhorado
BR112015017815A2 (pt) método para prever o início dos sintomas extrapiramidais (eps) induzidos por um tratamento a base de antipsicótico
CR20140473A (es) Compuestos de pirazol como inhibidores de sglt1
CL2015003563A1 (es) Marcador para trastornos de la esfingomielinasa ácida y sus usos.
BR112015020667A2 (pt) método de preparar inibidores de glucosilceramida sintase
MX2015017535A (es) Tratamiento de resistencia a la insulina a traves de inhibidores del factor de transcripcion tsc22d4.
UA78641U (ru) Способ прогнозирования тяжести больных острым панкреатитом
BR112014019274A2 (pt) métodos relacionados ao tratamento de doenças e distúrbios inflamatórios
BR112017020783A2 (pt) tratamento de dor
Tatar Neuroleptic malignant syndrome: case report
UA96918U (uk) Спосіб прогнозування зрощення перелому
AR102226A1 (es) Métodos para personalizar la terapia contra el cáncer de un paciente con un antagonista de mdm2
UA96300U (uk) Спосіб прогнозування зрощення перелому

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/01/2014, OBSERVADAS AS CONDICOES LEGAIS